Navigation Links
Myriad Genetics Presents Tumor Origin Technology at AACR

delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2006, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.


'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Tumor Origin Technology AACR
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... specialist, Dr. James Strawbridge, gives a new approach on solutions in his new ... with the employer and employees getting together for meaningful group meetings. "This would ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
(Date:8/28/2015)... ... , ... The Quatela Center for Plastic Surgery is excited to bring patients ... approved by the Food and Drug Administration to eliminate submental fat, also known as ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an innovative leader ... and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee ... which delivers a variety of sizes and styles while achieving the perfect brew ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... TCS Founder Pock Presents Gift to CMSA Foundation President ... AUBURN, Calif., July 16 TCS Healthcare Technologies (TCS), ... an unrestricted grant of $5,000 to the Case Management Society of America ... , , Rob Pock, TCS ...
... HOFFMAN ESTATES, Ill., July 16 St. Alexius Medical Center, Hoffman Estates, ... annual America,s Best Hospitals list published by U.S. News ... ranked among the top 50 hospitals in the nation for the treatment ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090716/CG47487 ) , , ...
... Calif., July 16 MO BIO Laboratories, Inc., the ... of an innovative new product, PowerFood(TM) Microbial DNA Isolation Kit, designed ... , The PowerFood Microbial DNA Isolation Kit ... that allows for isolation of DNA from a variety of gram ...
... , , PALO ALTO, Calif., July ... been elected chairman of the company,s Board of Directors. , ... biotechnology industry, and as the former chairman of Connetics Corporation and ... and success to TOPICA, as well as an exceptional knowledge of ...
... , , CHICAGO, July 16 ... provides health care services for those needing sub-acute medical and ... its board of directors has named Dale Zaletel as the ... Zaletel, who previously held the position of Chief Operating Officer ...
... , , Gamers Engage ... NEW YORK, July 16 /PRNewswire-USNewswire/ -- The MS ... sclerosis (MS) to exercise their brain power. The Collaborative, an alliance ... announced the launch of MyBrainGames, a free suite of online cognitive games ...
Cached Medicine News:Health News:TCS Healthcare Technologies Provides $5,000 Seed Money to Help Fund New CMSA Foundation 2Health News:TCS Healthcare Technologies Provides $5,000 Seed Money to Help Fund New CMSA Foundation 3Health News:St. Alexius Medical Center Named to America's Best Hospitals Rankings 2Health News:MO BIO Laboratories, Inc. Launches PowerFood(TM) Microbial DNA Isolation Kit 2Health News:TOPICA Elects G. Kirk Raab as Chairman of the Board 2Health News:Lexington Health Care Names New Chief Executive Officer 2Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 2Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 3Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 4
... Are Turned 90 Degrees To Allow ... While Incising Tissue. ,Special Mirror-Polished Double Footplate ... Blade Extension Settings Of 0.5mm, 0.55mm, ... Extension.,1mm Wide Snub Nose Diamond Blade ...
... Unique In-Line Footplates Are Turned ... Of The Diamond Blade While Incising ... Precise Blade Depth Penetration.,Pre-Set Blade Extension ... Full Retraction And Full Extension.,1mm Wide ...
... 23g Tube Allows Use Through A ... More Comfortable Approach To The Incision.,Cystotome ... Capsule To Initiate And Complete A ... Weight For Improved Ergonomic Feel. Ideal ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: